SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (2781)10/11/2012 3:48:54 PM
From: Biomaven  Read Replies (1) | Respond to of 3202
 
Those are good numbers - ACR50 at 6 months for Enbrel is typically around 40% if I recall correctly.

Peter



To: scaram(o)uche who wrote (2781)10/11/2012 4:16:30 PM
From: Pravda  Read Replies (1) | Respond to of 3202
 
If I'm reading this right, the comparable for tofacitinib at 6 months is:

58.3% patients achieved ACR20, 36.6% ACR50 and 16.2% ACR70

Pravda

sciencedaily.com